Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

CANCER THERAPY

Bispecific antibodies seek out colon cancer stem cells

Nature Cancer volume 3, pages 379–380 (2022)Cite this article

Subjects

Patients with KRAS-mutant colorectal cancers do not respond to cetuximab, a monoclonal antibody against EGFR. A new proof-of-concept study presents a bispecific antibody with the ability to trigger EGFR degradation in LGR5+ cancer stem cells, and robust anti-tumor activity in KRAS-mutant and wild-type colorectal cancers.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: A bispecific antibody that specifically triggers EGFR degradation in LGR5+ colorectal CSCs.

References

  1. Batlle, E. & Clevers, H. Nat. Med. 23, 1124–1134 (2017).

    Article  CAS  Google Scholar 

  2. Shimokawa, M. et al. Nature 545, 187–192 (2017).

    Article  CAS  Google Scholar 

  3. de Sousa e Melo, F. et al. Nature 543, 676–680 (2017).

    Article  Google Scholar 

  4. Tian, H. et al. Nature 478, 255–259 (2011).

    Article  CAS  Google Scholar 

  5. Jonker, D. J. et al. N. Engl. J. Med. 357, 2040–2048 (2007).

    Article  CAS  Google Scholar 

  6. Karapetis, C. S. et al. N. Engl. J. Med. 359, 1757–1765 (2008).

    Article  CAS  Google Scholar 

  7. Matano, M. et al. Nat. Med. 21, 256–262 (2015).

    Article  CAS  Google Scholar 

  8. Herpers, B. et al. Nat. Cancer https://doi.org/10.1038/s43018-022-00359-0 (2022).

  9. van de Wetering, M. et al. Cell 161, 933–945 (2015).

    Article  Google Scholar 

  10. Fujii, M. et al. Cell Stem Cell 18, 827–838 (2016).

    Article  CAS  Google Scholar 

  11. The Cancer Genome Atlas Network. Nature 487, 330–337 (2012).

    Article  Google Scholar 

  12. Snyder, J. C. et al. J. Biol. Chem. 288, 10286–10297 (2013).

    Article  CAS  Google Scholar 

  13. Fumagalli, A. et al. Cell Stem Cell 26, 569–578 (2020).

    Article  CAS  Google Scholar 

  14. Argiles, G. et al. J. Clin. Oncol. 39, 62–62 (2021).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biology, The David H. Koch Institute for Integrative Cancer Research at MIT, Massachusetts Institute of Technology, Cambridge, MA, USA

    Norihiro Goto & Ömer H. Yilmaz

  2. Broad Institute of MIT and Harvard, Cambridge, MA, USA

    Ömer H. Yilmaz

  3. Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

    Ömer H. Yilmaz

Authors
  1. Norihiro Goto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ömer H. Yilmaz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ömer H. Yilmaz.

Ethics declarations

Competing interests

O.H.Y. is a member of the scientific advisory board of AVA Therapeutics.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Goto, N., Yilmaz, Ö.H. Bispecific antibodies seek out colon cancer stem cells. Nat Cancer 3, 379–380 (2022). https://doi.org/10.1038/s43018-022-00368-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43018-022-00368-z

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer